<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944736</url>
  </required_header>
  <id_info>
    <org_study_id>09 06-115</org_study_id>
    <nct_id>NCT00944736</nct_id>
  </id_info>
  <brief_title>Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease</brief_title>
  <official_title>Effect of Probiotic VSL#3 on Intestinal Permeability of Pediatric Patients With Crohn's Disease in Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VSL Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a probiotic formulation, VSL#3, on&#xD;
      intestinal permeability in pediatric patients with Crohn's disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Children with Crohn's disease have altered intestinal permeability. A pilot study in children&#xD;
      showed that probiotics may decrease intestinal permeability. In this double blind, randomized&#xD;
      controlled trial, we will observe the effect of VSL#3 on small bowel permeability using a&#xD;
      double sugar absorption test. PCDAI was monitored, but not analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal Permeability - measured by Sugar Absorption Test</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>VSL#3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VSL#3</intervention_name>
    <description>1 packet BID</description>
    <arm_group_label>VSL#3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 inactive packet BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of small bowel or colonic Crohn's disease as defined by histological&#xD;
             and endoscopic criteria.&#xD;
&#xD;
          -  Males or females ages 11-17 years.&#xD;
&#xD;
          -  Crohn's disease in remission as defined by a Pediatric Crohn's Disease Activity Index&#xD;
             (PCDAI) &lt; 10&#xD;
&#xD;
          -  Patients on maintenance doses of aminosalicylates, 6-MP and/or Azathioprine for at&#xD;
             least 2 months.&#xD;
&#xD;
          -  Procurement of written informed consent signed by the subject's legal guardian and&#xD;
             study investigator(s) and patient assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with documented intestinal stricture.&#xD;
&#xD;
          -  Patients with signs of symptoms of systemic or intestinal infection.&#xD;
&#xD;
          -  Antibiotic use the previous 1 month.&#xD;
&#xD;
          -  Probiotic use in the previous 2 months (excluding yogurt).&#xD;
&#xD;
          -  Use of the following medications; Methotrexate, Cyclosporine, Tacrolimus and&#xD;
             Infliximab.&#xD;
&#xD;
          -  Patients with diagnosis of other co-morbid diseases such as heart disease, renal&#xD;
             disease, immunodeficiency, diabetes, or thyroid disease.&#xD;
&#xD;
          -  Patients with indwelling catheters.&#xD;
&#xD;
          -  Patients with short bowel syndrome&#xD;
&#xD;
          -  Positive urine pregnancy test for female subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia M Bracken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>March 6, 2014</last_update_submitted>
  <last_update_submitted_qc>March 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Julia Bracken</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Pediatric</keyword>
  <keyword>VSL#3</keyword>
  <keyword>Permeability</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Zonulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

